Related Experiment Video

Updated: Nov 1, 2025

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

18.9K

PARP and CDK4/6 Inhibitor Combination Therapy Induces Apoptosis and Suppresses Neuroendocrine Differentiation in

Cheng Wu1,2, Shan Peng1,3, Patrick G Pilié1

  • 1Genitourinary Medical Oncology Department, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Molecular Cancer Therapeutics
|June 23, 2021
PubMed

Insights

This study shows that combining PARP inhibition (PARPi) with CDK4/6 inhibition effectively treats castration-resistant and neuroendocrine prostate cancer by blocking cell growth and promoting cancer cell death.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Castration-resistant prostate cancer (CRPC) and neuroendocrine prostate cancer (NEPC) are aggressive forms of prostate cancer with limited treatment options.
  • PARP inhibitors (PARPi) and CDK4/6 inhibitors (CDK4/6i) are emerging targeted therapies with potential in prostate cancer treatment.

Purpose of the Study:

  • To investigate the efficacy and mechanistic interactions of combining PARP inhibition (olaparib) with CDK4/6 inhibition (palbociclib or abemaciclib) in CRPC and NEPC models.
  • To elucidate the molecular mechanisms underlying the synergistic effects of this combination therapy.

Main Methods:

  • Utilized in vitro and in vivo models of CRPC and NEPC.
  • Analyzed the effects of olaparib, palbociclib, abemaciclib, and their combinations on cell-cycle progression, apoptosis, and specific signaling pathways.
  • Investigated the roles of the p-Rb1-E2F1 axis, CDK1, and BCL-2 family members in mediating the combination therapy's effects.

Main Results:

  • Combination therapy with olaparib and palbociclib or abemaciclib demonstrated synergistic suppression of the p-Rb1-E2F1 signaling axis.
  • The combination treatment led to cell-cycle arrest, inhibition of E2F1 target genes (including DNA damage repair, antiapoptotic BCL-2 family members, CDK1, and neuroendocrine differentiation markers), and significantly enhanced apoptosis and growth inhibition compared to single agents.
  • CDK1 inhibition was identified as a key mediator of the combination's effects on BCL-2 and apoptosis.

Conclusions:

  • Combination PARPi and CDK4/6i represents a novel and effective treatment strategy for CRPC and NEPC.
  • The synergistic effect is mediated by the suppression of the p-Rb1-E2F1 axis and its downstream targets, including CDK1 and neuroendocrine differentiation markers.
  • This study provides a strong molecular rationale for clinical trials evaluating PARPi and CDK4/6i combinations in patients with NEPC.

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.4K
Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog08:37

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Published on: November 5, 2014

10.1K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.7K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.8K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
37.0K